Christopher Griffiths
Impact in
- Immunology top 0.01%
- Psoriasis: Treatment and Pathogenesis
- Dermatology top 0.01%
- Dermatology and Skin Diseases
- Skin Protection and Aging
- Dermatologic Treatments and Research
Papers in
- Immunology 556
- Psoriasis: Treatment and Pathogenesis 530
- Dermatology 208
- Skin Protection and Aging 104
- Dermatology and Skin Diseases 73
- Contact Dermatitis and Allergies 17
- Co-authors
- Darren Mark Ashcroft (72 shared papers)Brian J. Nickoloff (25 shared papers)Rosa Parisi (21 shared papers)John J. Voorhees (41 shared papers)Helen L. Richards (38 shared papers)Dónal G. Fortune (29 shared papers)Deborah P. M. Symmons (6 shared papers)Kim Alexander Papp (32 shared papers)
- Journals
- British Journal of Dermatology (283 papers)Journal of Investigative Dermatology (89 papers)Journal of the European Academy of Dermatology and Venereology (50 papers)Clinical and Experimental Dermatology (49 papers)Journal of the American Academy of Dermatology (40 papers)
- Partner nations
- United KingdomUnited StatesGermany
In The Last Decade
Christopher Griffiths
874 papers receiving 56k citations
Christopher Griffiths's Hit Papers
Peers
Comparison fields: 5 of 197
- Immunology 31.4k
- Dermatology 10.4k
- Rheumatology 4.2k
- Urology 1.2k
- Family Practice 361
Countries citing papers authored by Christopher Griffiths
This map shows the geographic impact of Christopher Griffiths's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Griffiths with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Griffiths more than expected).
Fields of papers citing papers by Christopher Griffiths
This network shows the impact of papers produced by Christopher Griffiths. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Griffiths. The network helps show where Christopher Griffiths may publish in the future.
Co-authors
The 25 scholars most cited alongside Christopher Griffiths, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 929 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence Hit paper breakdown → | 2012 | 2099 |
| 2 | Pathogenesis and clinical features of psoriasis Hit paper breakdown → | 2007 | 1752 |
| 3 | Psoriasis Hit paper breakdown → | 2021 | 1713 |
| 4 | Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials Hit paper breakdown → | 2014 | 1674 |
| 5 | Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial Hit paper breakdown → | 2017 | 1047 |
| 6 | Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial Hit paper breakdown → | 2005 | 899 |
| 7 | National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study Hit paper breakdown → | 2020 | 891 |
| 8 | A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1 Hit paper breakdown → | 2010 | 884 |
| 9 | Psoriasis: epidemiology, clinical features, and quality of life Hit paper breakdown → | 2005 | 869 |
| 10 | Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity Hit paper breakdown → | 2012 | 838 |
| 11 | Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials Hit paper breakdown → | 2015 | 723 |
| 12 | Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial Hit paper breakdown → | 2017 | 721 |
| 13 | Definition of treatment goals for moderate to severe psoriasis: a European consensus Hit paper breakdown → | 2010 | 712 |
| 14 | 2010 | 703 | |
| 15 | Keratinocytes as initiators of inflammation Hit paper breakdown → | 1991 | 671 |
| 16 | 2009 | 599 | |
| 17 | 2005 | 591 | |
| 18 | Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1) Hit paper breakdown → | 2015 | 557 |
| 19 | 2005 | 490 | |
| 20 | 1989 | 468 |
About Christopher Griffiths
Christopher Griffiths is a scholar working on Immunology, Dermatology, Rheumatology, Urology and Pathology and Forensic Medicine, having authored 929 papers that have together received 59k indexed citations. Recurring topics across this work include Psoriasis: Treatment and Pathogenesis (530 papers), Skin Protection and Aging (104 papers), Dermatology and Skin Diseases (73 papers), Hair Growth and Disorders (19 papers), Contact Dermatitis and Allergies (17 papers), Spondyloarthritis Studies and Treatments (17 papers), Systemic Sclerosis and Related Diseases (16 papers) and Retinoids in leukemia and cellular processes (16 papers). The work is most often cited by research in Immunology (31.4k citations), Dermatology (10.4k citations), Rheumatology (4.2k citations), Urology (1.2k citations) and Family Practice (361 citations). Christopher Griffiths has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include Darren Mark Ashcroft, Brian J. Nickoloff, Rosa Parisi, John J. Voorhees, Helen L. Richards, Dónal G. Fortune, Deborah P. M. Symmons, Kim Alexander Papp, Chris J. Main and Richard G B Langley. Their work appears in journals such as British Journal of Dermatology, Journal of Investigative Dermatology, Journal of the European Academy of Dermatology and Venereology, Clinical and Experimental Dermatology and Journal of the American Academy of Dermatology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.